Biogen Inc (BIIB)

287.77
NASDAQ : Health Care
Prev Close 289.54
Day Low/High 281.79 / 306.98
52 Wk Low/High 223.02 / 333.65
Avg Volume 1.60M
Exchange NASDAQ
Shares Outstanding 217.57M
Market Cap 63.00B
EPS 15.40
P/E Ratio 19.67
Div & Yield N.A. (N.A)

Latest News

Stocks on Track for Fresh Records as Health Care Sector Climbs

Stocks on Track for Fresh Records as Health Care Sector Climbs

Stocks are on track to close at fresh records on Friday as the health care sector makes a comeback after a bruising week.

Biogen Shares Up Following Eli Lilly's Failed Alzheimer's Study

Biogen Shares Up Following Eli Lilly's Failed Alzheimer's Study

Shares of Biogen soared Friday after the biotech company's early clinical trial data of its experimental Alzheimer's drug was leaked and Eli Lilly's study failed.

Jim Cramer -- Be Careful With Biogen; Apple Is Waking Up

Jim Cramer -- Be Careful With Biogen; Apple Is Waking Up

Jim Cramer says investors need to be careful speculating on Biogen's treatment for Alzheimer's while investors came away from Broadcom's earnings with a more positive vibe on Apple.

Attention Shifts to Biogen's Alzheimer's Drug in Wake of Lilly Results

Attention Shifts to Biogen's Alzheimer's Drug in Wake of Lilly Results

Lilly's sola study did not reduce amyloid plaques in the brain, adding to the likelihood that Biogen's late-stage Alzheimer's study will prove successful.

Stocks Extend Rally as Health Care Sector Makes Comeback

Stocks Extend Rally as Health Care Sector Makes Comeback

Stocks move higher on Friday, trading at records, as the health care sector makes a comeback after a bruising week.

Biogen Presents Data From Phase 1b Study Of Investigational Alzheimer's Disease Treatment Aducanumab At 2016 Clinical Trials On Alzheimer's Disease Meeting

Biogen Presents Data From Phase 1b Study Of Investigational Alzheimer's Disease Treatment Aducanumab At 2016 Clinical Trials On Alzheimer's Disease Meeting

Biogen (NASDAQ: BIIB) announced it will present new data from the Phase 1b (PRIME) study of aducanumab, its investigational treatment for early Alzheimer's disease (AD), today at the 9 th Clinical Trials on...

Biogen Shares Spike on Leaked Alzheimer's Drug Data

Biogen Shares Spike on Leaked Alzheimer's Drug Data

Shares are Biogen spiked on the aducanumab data leak as investors with unfair access to what was supposed to be embargoed results traded on the information.

BIIB SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Shareholders Of A Class Action Involving Biogen Inc. And A Lead Plaintiff Deadline Of December 23, 2016

BIIB SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Shareholders Of A Class Action Involving Biogen Inc. And A Lead Plaintiff Deadline Of December 23, 2016

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of Massachusetts on behalf of investors who purchased Biogen Inc.

Http://www.sobi.com

Http://www.sobi.com

Biogen (NASDAQ: BIIB) and Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) will present new data, including updated longitudinal safety and efficacy findings from phase 3 and extension studies, on the...

Biotech Stock Mailbag: Looking for an Investable Idea in Alzheimer's Minefield

Biotech Stock Mailbag: Looking for an Investable Idea in Alzheimer's Minefield

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

C, AAPL, FB: Jim Cramer's Views

C, AAPL, FB: Jim Cramer's Views

Cramer shares his views on how much further Citigroup and Goldman Sachs have to run and cautions that you can't wait for everyone to love a stock.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Biogen Inc. Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of December 23, 2016

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Biogen Inc. Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of December 23, 2016

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Biogen Inc.

Biotech Hits an Inflection Point

Biotech Hits an Inflection Point

The worst appears to be over for this sector; we could see big growth ahead.

Eli Lilly's Alzheimer's Drug Fails Key Clinical Trial

Eli Lilly's Alzheimer's Drug Fails Key Clinical Trial

Based on the negative study results, Lilly will not pursue regulatory approvals for solanezumab in Alzheimer's disease.

Cramer: Trump Rally is a FANG + FANG Affair

Cramer: Trump Rally is a FANG + FANG Affair

Today high-growth tech and natural resources stocks are both going higher without sending much lower at all.

Bullish and Bearish Reversals for the Week

Bullish and Bearish Reversals for the Week

The bullish side dominates, with consumer cyclicals and energy names most prevalent.

BIIB SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Shareholders Of A Class Action Involving Biogen Inc. And A Lead Plaintiff Deadline Of December 23, 2016

BIIB SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Shareholders Of A Class Action Involving Biogen Inc. And A Lead Plaintiff Deadline Of December 23, 2016

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of Massachusetts on behalf of investors who purchased Biogen Inc.

Biotech Stocks May be Cheap But Large Scale M&A May Elude the Sector

Biotech Stocks May be Cheap But Large Scale M&A May Elude the Sector

Investors in biotech stocks appear to be happy with a Trump win and Mizuho's senior biotech analyst says companies in the sector could continue to climb in 2017.

2 Small-Cap Biotech Buyout Targets

2 Small-Cap Biotech Buyout Targets

With the election resolved, biotech could be ripe for consolidation.

Eli Lilly's Alzheimer's Drug Study Results Are Coming -- Here's What Investors Need to Know

Eli Lilly's Alzheimer's Drug Study Results Are Coming -- Here's What Investors Need to Know

In a few weeks, investors will know if Lilly's solanezumab is a groundbreaking treatment for Alzheimer's or another drug casualty to a disease that has eluded pharmaceutical companies for years.

Biogen Announces Additional Members Of Management Team Of Hemophilia Spin-off Company Bioverativ

Biogen Announces Additional Members Of Management Team Of Hemophilia Spin-off Company Bioverativ

Biogen (NASDAQ: BIIB) today announced the addition of two members to the executive management team of Bioverativ Inc.

Stocks Surge After Trump Victory

Stocks Surge After Trump Victory

Stocks close at session highs on Wednesday as the idea of a Trump presidency settles in. Financial and health care sectors lead the market.

Stocks Maintain Solid Gains After Donald Trump Wins the White House

Stocks Maintain Solid Gains After Donald Trump Wins the White House

Stocks post solid gains Wednesday after plunging overnight following Donald Trump's surprising victory in the U.S. presidential race.

Midday Report: Stocks Higher As Wall Street Shrugs Off Trump's Presidential Election

Midday Report: Stocks Higher As Wall Street Shrugs Off Trump's Presidential Election

U.S. stocks rallied slightly in midday trading as energy, financials, and healthcare sectors saw green on Wednesday following the surprise election of Republican Donald Trump.

Stocks Turn Positive After Trump's Surprising Election Win

Stocks Turn Positive After Trump's Surprising Election Win

Stocks turn positive Wednesday as investors gauge a Donald Trump presidency on markets. Drug, biotech and financial stocks jump.

Drug and Biotech Stocks Rise as Price Clampdown Fears Ease Under Trump Presidency (Updated)

Drug and Biotech Stocks Rise as Price Clampdown Fears Ease Under Trump Presidency (Updated)

How health care investors deal with Donald Trump as the next U.S. president and Republicans maintaining control of Congress is hard to forecast because few envisioned this scenario playing out.